Annual and transition report of foreign private issuers pursuant to Section 13 or 15(d)

Consolidated Statements of Comprehensive Loss

v3.21.1
Consolidated Statements of Comprehensive Loss - USD ($)
12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Income Statement [Abstract]      
Revenues $ 478,520 $ 460,739 $ 88,691
Cost of revenues 236,493 388,265 94,238
Amortization of intangible assets 428,431 470,773 37,694
Gross loss 186,404 398,299 43,241
Operating expenses:      
Research and development 987,444 1,090,295 787,025
Less - research and development grants (256,423) (314,652) (382,134)
Research and development, net 731,021 775,643 404,891
Sales and marketing 673,983 550,008 480,963
General and administrative 1,319,239 1,297,711 1,227,632
Goodwill impairment 161,381
Acquisition related costs 750,956
Total operating expenses 2,724,243 2,784,743 2,864,442
Operating loss 2,910,647 3,183,042 2,907,683
Financial expenses (income), net 1,042,358 (1,210,484) (63,778)
Net loss $ 3,953,005 $ 1,972,558 $ 2,843,905
Net loss per ordinary share:      
Basic and diluted net loss per ordinary share (in Dollars per share) $ 0.16 $ 0.09 $ 0.19
Weighted average number of ordinary shares used in computing basic and diluted net loss per ordinary share (in Shares) 24,071,186 23,142,850 15,249,947